<DOC>
	<DOCNO>NCT02388581</DOCNO>
	<brief_summary>Aims : A nationwide study prospectively validate 1 . The complete histological molecular remission rate antibiotic 1st-line therapy early-stage Hp-positive gastric pure ( de novo ) DLBCL 2 . The durability complete histological remission antibiotic 3 . The usefulness pattern NF-kB , BCL10 , BAFF , CagA IHC stain prospectively predict Hp-dependence gastric pure ( de novo ) DLBCL 4 . The frequency ( 11 ; 18 ) ( q21 ; q21 ) translocation gastric pure ( de novo ) DLBCL Taiwan . 5 . The association CYP2C18/CYP2C19 genetic polymorphism eradication Hp infection antibiotic .</brief_summary>
	<brief_title>First-line Antibiotic Therapy Early-stage HP ( + ) Gastric Pure DLBCL</brief_title>
	<detailed_description>The study validate use antibiotic first-line therapy stage IE ( perhaps IIE-1 ) Hp-positive gastric pure ( de novo ) DLBCL . The status NF-kB , BCL10 , BAFF , CagA IHC nuclear stain help tailor treatment early-stage gastric pure ( de novo ) DLBCL . And 50-60 % stage IE / IIE-1 pure ( de novo ) DLBCL patient cure 2-weeks antibiotic rather 6-months relatively toxic front-line systemic chemotherapy . The investigator shall also elucidate distribution CYP2C18/19 patient pure ( de novo ) DLBCL association efficacy sequential antibiotic eradication Hp infection .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>1 . Patients must histologically confirm H. pyloripositive primary gastric pure ( de novo ) gastric DLBCL . 2 . Patient must prior chemotherapy radiotherapy his/her gastric pure ( de novo ) gastric DLBCL . 3 . Patients must evaluable disease endoscopy and/or compute tomography . 4 . Patients must document H. pylori infection treatment , follow test show positive result : histology , rapid urease test ( CLOtest ) , C13 urease breath test , serology . 5 . Patients must either stage IE IIE1 disease , accord adaptation Ann Arbor stag system modify Musshoff primary extranodal lymphoma . 6 . Patients either newly diagnose already start antiH . pylori therapy followup endoscopy biopsy eligible . 7 . Patient must sign informed consent , agree provide achieve pathologic material immunohistochemical / fluorescence situ hybridization study RTPCR ( 11 ; 18 ) ( q21 ; q21 ) determination . 1 . Patients extensive gastrointestinal tract involvement . 2 . Patients previous history extranodal lymphoma . 3 . Patients stage IIE2 beyond disease : infiltration regional lymph node . 4 . Patients cardiopulmonary status allow repeat endoscopy . 5 . Patients prior chemotherapy radiotherapy primary gastric lymphoma . 6 . Patients previous antiH . pylori therapy without pretreatment pathology achieve material histological review immunohistochemical study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Helicobactor pylorus , Hp</keyword>
	<keyword>mucosa-associated lymphoid tissue-type lymphoma , MALToma</keyword>
</DOC>